Literature DB >> 16491163

Interleukin-9 as a possible therapeutic target in both asthma and chronic obstructive airways disease.

Paul S McNamara1, Rosalind L Smyth.   

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are important causes of morbidity and mortality worldwide. Both asthma and COPD are characterized by airflow limitation but distinct differences occur in the pulmonary inflammatory responses in the two conditions. Treatment options for asthma and COPD are limited (especially so for COPD), and both are in need of novel therapeutic interventions. Interleukin-9 (IL-9) is a potential target for such a therapy. This Th2-type cytokine, is secreted by a number of different cell types, and has multiple effects on a wide range of cells within the lung. In this review we will summarize current knowledge about the immunobiology of IL-9 and discuss the role played by IL-9 in inflammation in both asthma and COPD, and its potential as a therapeutic target. (c) 2005 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16491163     DOI: 10.1358/dnp.2005.18.10.959575

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  4 in total

1.  IL-9 Controls Central Nervous System Autoimmunity by Suppressing GM-CSF Production.

Authors:  Satoshi Yoshimura; Rodolfo Thome; Shingo Konno; Elisabeth R Mari; Javad Rasouli; Daniel Hwang; Alexandra Boehm; Yanhua Li; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  J Immunol       Date:  2019-12-18       Impact factor: 5.422

2.  Oxytetracycline attenuates allergic airway inflammation in mice via inhibition of the NF-κB pathway.

Authors:  Xinxin Ci; Xiao Chu; Chi Chen; Xiangchao Li; Shuhan Yan; Xinrui Wang; Yongjun Yang; Xuming Deng
Journal:  J Clin Immunol       Date:  2010-12-07       Impact factor: 8.317

Review 3.  Macrophage-derived cytokines in pneumonia: Linking cellular immunology and genetics.

Authors:  Marina Dukhinova; Elena Kokinos; Polina Kuchur; Alexey Komissarov; Anna Shtro
Journal:  Cytokine Growth Factor Rev       Date:  2020-12-03       Impact factor: 7.638

4.  New drugs targeting Th2 lymphocytes in asthma.

Authors:  Gaetano Caramori; David Groneberg; Kazuhiro Ito; Paolo Casolari; Ian M Adcock; Alberto Papi
Journal:  J Occup Med Toxicol       Date:  2008-02-27       Impact factor: 2.646

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.